SENORES PHARMACEUTICALS L Latest Share Price (SENORES)
TODAY IN ONE LINE
SENORES is little changed at ₹1428.40 on light volume — a quiet consolidation day, supported by recent strong earnings.
With a market cap of ₹6,581.98 Cr., it trades at a P/E of 50.84. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
SENORES PHARMACEUTICALS L flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 108.9% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 567.7% and Profit up 2856.3%
- ●Healthy Operating MarginsOPM is structurally strong at 28.4%
- ●FII AccumulationFII holding increased by 2.98% QoQ
Red Flags
- ●Low Promoter HoldingPromoters hold only 6.3%
- ●Promoter Pledging DetectedPledge activity recorded on 17-Feb-2026 12:33
Latest SENORES PHARMACEUTICALS L News
What changed recently?
Recent events, corporate actions, and announcements.
SENORES PHARMACEUTICALS L valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for SENORES PHARMACEUTICALS L, framed against the sector median so the premium or discount is obvious at a glance.
SENORES PHARMACEUTICALS L trades at a P/E of 50.84× and P/B of 7.16×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
SENORES PHARMACEUTICALS L technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for SENORES PHARMACEUTICALS L — derived from the latest tape, not yesterday's close.
SENORES PHARMACEUTICALS L last traded at ₹1,428.4 with an intraday range of ₹1,420–₹1,465.9 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1428.40| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1548.00 | +119.60 | +8.37% |
| R3 | 1502.10 | +73.70 | +5.16% |
| R2 | 1484.00 | +55.60 | +3.89% |
| R1 | 1456.20 | +27.80 | +1.95% |
| PIVOT | 1438.10 | 9.70 | 0.68% |
| CURRENT | 1428.40 | — | — |
| S1 | 1410.30 | -18.10 | -1.27% |
| S2 | 1392.20 | -36.20 | -2.53% |
| S3 | 1364.40 | -64.00 | -4.48% |
| S4 | 1318.50 | -109.90 | -7.69% |
SENORES is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹1435.4–₹1465.9
Trading Inside opening range
SENORES PHARMACEUTICALS L financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for SENORES PHARMACEUTICALS L — consolidated or standalone — with margins, YoY growth and key ratios inline.
SENORES PHARMACEUTICALS L reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹6,581.98 Cr. and reported EPS of ₹6.67.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 398 | 633 ▲ 58.9% |
| Sales Growth YoY %Derived | — | 58.85% |
| Other Income | 19 | 47 ▲ 144.3% |
| Total Income | 418 | 680 ▲ 62.8% |
| 181 | 252 ▲ 39.3% | |
| Gross ProfitDerived | 218 | 381 ▲ 75.1% |
| Gross Margin %Derived | 54.63% | 60.22% |
| 128 | 213 ▲ 66.3% | |
| EBITDA (Operating Profit)Derived | 90 | 168 ▲ 87.6% |
| OPM %Derived | 22.52% | 26.61% |
| 38 | 56 ▲ 46.6% | |
| Profit Before Tax (PBT) | 71 | 159 ▲ 125.4% |
| 12 | 38 ▲ 207.2% | |
| Effective Tax %Derived | 17.33% | 23.61% |
| Total Profit for Period | 58 | 122 ▲ 108.3% |
| Net Profit (Owner's PAT)Derived | 58 | 122 ▲ 108.3% |
| Net Profit Margin %Derived | 14.65% | 19.21% |
| PAT Growth YoY %Derived | — | 108.31% |
| Earnings Per Share (EPS ₹) | 12.67 | 26.39 ▲ 108.3% |
| Diluted Shares Outstanding (Cr) | 5 | 5 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -4 | 29 ▲ 926.9% |
| Total Expenses (incl. D&A & Interest) | 347 | 521 ▲ 50.1% |
| Material Cost % of RevenueDerived | 23.01% | 18.06% |
| Employee Cost % of RevenueDerived | 15.16% | 17.74% |
| Other Cost % of RevenueDerived | 16.94% | 15.87% |
| Interest Coverage (x)Derived | 3.38x | 5.48x |
| Period | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|
| Revenue from Operations | 398 | 633 ▲ 58.9% | |
| Sales Growth YoY %Derived | — | 58.85% | |
| Other Income | 19 | 47 ▲ 144.3% | |
| Total Income | 418 | 680 ▲ 62.8% | |
181 | 252 ▲ 39.3% | ||
| Gross ProfitDerived | 218 | 381 ▲ 75.1% | |
| Gross Margin %Derived | 54.63% | 60.22% | |
128 | 213 ▲ 66.3% | ||
| EBITDA (Operating Profit)Derived | 90 | 168 ▲ 87.6% | |
| OPM %Derived | 22.52% | 26.61% | |
38 | 56 ▲ 46.6% | ||
| Profit Before Tax (PBT) | 71 | 159 ▲ 125.4% | |
12 | 38 ▲ 207.2% | ||
| Effective Tax %Derived | 17.33% | 23.61% | |
| Total Profit for Period | 58 | 122 ▲ 108.3% | |
| Net Profit (Owner's PAT)Derived | 58 | 122 ▲ 108.3% | |
| Net Profit Margin %Derived | 14.65% | 19.21% | |
| PAT Growth YoY %Derived | — | 108.31% | |
| Earnings Per Share (EPS ₹) | 12.67 | 26.39 ▲ 108.3% | |
| Diluted Shares Outstanding (Cr) | 5 | 5 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -4 | 29 ▲ 926.9% | |
| Total Expenses (incl. D&A & Interest) | 347 | 521 ▲ 50.1% | |
| Material Cost % of RevenueDerived | 23.01% | 18.06% | |
| Employee Cost % of RevenueDerived | 15.16% | 17.74% | |
| Other Cost % of RevenueDerived | 16.94% | 15.87% | |
| Interest Coverage (x)Derived | 3.38x | 5.48x |
SENORES PHARMACEUTICALS L segment analysis : revenue and profit mix.
Disclosed business segments at SENORES PHARMACEUTICALS L with their share of revenue and profit, switchable between consolidated and standalone reporting.
SENORES PHARMACEUTICALS L discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for SENORES PHARMACEUTICALS L.
Our AI distills the core fundamental drivers supporting SENORES PHARMACEUTICALS L, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
SENORES PHARMACEUTICALS L's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
TTM EPS grew 108.9% YoY, showcasing exceptional earnings momentum and profitability.
Operating margin 21.67% demonstrates strong cost efficiency and pricing power.
Net margin 18.24% exceeds peer averages, reflecting operational excellence.
Debt-to-equity 0.0010 maintains minimal leverage, ensuring financial stability.
TTM revenue grew 53.4% YoY, indicating strong market demand acceleration.
Key Risks.
P/E ratio 49.64x significantly exceeds peer median, indicating overvaluation risk.
Zero dividend yield offers no income to shareholders, limiting appeal.
Operating cash flow negative ₹26.88 Cr in FY2026 signals liquidity strain.
Stock trading near 52-week high ₹1,563.00, limiting upside potential significantly.
ROCE 2.92% and ROE 2.70% lag peer averages, showing capital inefficiency.
Flip Conditions.
Valuation risk. a P/E above 66 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
SENORES PHARMACEUTICALS L peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — SENORES PHARMACEUTICALS L is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
SENORES PHARMACEUTICALS L chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for SENORES PHARMACEUTICALS L — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
SENORES PHARMACEUTICALS L delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for SENORES PHARMACEUTICALS L over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in SENORES PHARMACEUTICALS L stood at 36.7% of traded volume, against a 20-day average of 43.6%.
SENORES PHARMACEUTICALS L announcements: results, concalls, ratings, M&A.
Filings SENORES PHARMACEUTICALS L sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
SENORES PHARMACEUTICALS L files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 178 documents below.
Copy of Newspaper Publication
Senores Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication with respect to the 9th Annual General Meeting of the…
Shareholders meeting
Senores Pharmaceuticals Limited has informed the Exchange regarding Notice of 9th Annual General Meeting to be held on September 25, 2026
Analysts/Institutional Investor Meet/Con. Call Updates
Senores Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Copy of Newspaper Publication
Senores Pharmaceuticals Limited has informed the Exchange regarding copy of newspaper publication for pre dispatch of Annual Report for the…
Appointment
Senores Pharmaceuticals Limited has informed the Exchange regarding Appointment of Mrs Shilpa Sharma as Company Secretary & Compliance Officer of the…
Investor decks & rating reports.
SENORES PHARMACEUTICALS L dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue SENORES PHARMACEUTICALS L has declared, sequenced by announce and record date.
SENORES PHARMACEUTICALS L corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
SENORES PHARMACEUTICALS L insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in SENORES PHARMACEUTICALS L as reported to SEBI — buying and selling signals from the people who know the business best.
SENORES PHARMACEUTICALS L insider activity below tracks 60 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Swapnil Jatin Shah | Insider | 28 Mar 2026 | buy | +1.97 L | ₹16 Cr. | ₹812.00 |
| Viraj Ashokkumar Barot | Insider | 28 Mar 2026 | buy | +49.5 K | ₹4.02 Cr. | ₹812.00 |
| Renosen Pharmaceuticals Private Limited | Insider | 28 Mar 2026 | buy | +7.39 L | ₹60.01 Cr. | ₹812.00 |
| Sangeeta Mukur Barot | Insider | 28 Mar 2026 | buy | +61.5 K | ₹4.99 Cr. | ₹812.00 |
| Ashokbhai Vijaysinh Barot | Insider | 28 Mar 2026 | buy | +1.23 L | ₹9.99 Cr. | ₹812.00 |
| Swapnil Jatin Shah | Insider | 28 Mar 2026 | buy | +1.97 L | ₹16 Cr. | ₹812.00 |
| Viraj Ashokkumar Barot | Insider | 28 Mar 2026 | buy | +49.5 K | ₹4.02 Cr. | ₹812.00 |
| Renosen Pharmaceuticals Private Limited | Insider | 28 Mar 2026 | buy | +7.39 L | ₹60.01 Cr. | ₹812.00 |
| Sangeeta Mukur Barot | Insider | 28 Mar 2026 | buy | +61.5 K | ₹4.99 Cr. | ₹812.00 |
| Ashokbhai Vijaysinh Barot | Insider | 28 Mar 2026 | buy | +1.23 L | ₹9.99 Cr. | ₹812.00 |
About SENORES PHARMACEUTICALS L: business, sector, key facts.
What SENORES PHARMACEUTICALS L does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
SENORES PHARMACEUTICALS L operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: SENORES, BSE: 544319.
Senores Pharmaceuticals Limited is a pharmaceutical company with a global reach, operating primarily in India, the United States, and Canada, as well as exporting to other international markets. Their business model centers around the development, manufacturing, and sale of a diverse range of pharmaceutical products.
The company's product portfolio is extensive and caters to various therapeutic areas. It includes a wide array of dosage forms, such as tablets, capsules, liquids, dry syrups, and oral rehydration solutions. They also manufacture active pharmaceutical ingredients (APIs), which are the fundamental building blocks of many medications. A significant portion of their production focuses on critical care injectables, particularly within the categories of antibiotics, anti-bacterial, and anti-fungal medications, alongside blood line products. This demonstrates a commitment to providing essential medications for a range of health needs.
Beyond the core manufacturing and sales operations, Senores Pharmaceuticals Limited also offers consulting and licensing services. The nature of these services is not explicitly detailed, but it suggests that the company leverages its expertise and infrastructure to assist other businesses within the pharmaceutical sector. This diversification strengthens their overall market presence and revenue streams.
Founded in 2017 and headquartered in Ahmedabad, India, Senores Pharmaceuticals Limited's relatively recent establishment highlights its rapid growth and success within the competitive pharmaceutical industry. The company's international presence and diversified product and service offerings position it for continued expansion and influence in the global healthcare market.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about SENORES PHARMACEUTICALS L (SENORES).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of SENORES PHARMACEUTICALS L (SENORES)?
The current share price of SENORES PHARMACEUTICALS L (SENORES) is ₹1,428.40. Today, the stock has declined by ₹2.00 (0.14%), trading in a range of ₹1,420.00 to ₹1,465.90. The stock opened at ₹1,442.80 with a trading volume of 1,24,425 shares.
02Is SENORES PHARMACEUTICALS L stock a good investment for long-term?
SENORES PHARMACEUTICALS L can be considered for long-term investment based on several factors. The company has a market capitalization of ₹6,581.98 Cr., P/E ratio of 50.84, ROE of 12.6%, and ROCE of 11.43%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of SENORES PHARMACEUTICALS L stock?
The 52-week high price of SENORES PHARMACEUTICALS L (SENORES) is ₹1,599.00, while the 52-week low is ₹662.45. Currently trading at ₹1,428.40, the stock is 115.62% above its 52-week low and 10.67% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy SENORES PHARMACEUTICALS L stock at the current price?
Whether to buy SENORES PHARMACEUTICALS L stock at ₹1,428.40 depends on multiple factors. The stock is currently trading with a P/E ratio of 50.84 and P/B ratio of 7.16. Today's performance shows a loss of 0.14%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of SENORES PHARMACEUTICALS L and when is the next dividend?
SENORES PHARMACEUTICALS L offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹1,428.40, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of SENORES PHARMACEUTICALS L?
SENORES PHARMACEUTICALS L's key financial metrics include: P/E Ratio: 50.84, P/B Ratio: 7.16, ROE: 12.6%, ROCE: 11.43%, Dividend Yield: 0%, EPS: ₹6.67, Book Value: ₹209.44, and Debt-to-Equity: 0.34. The company's market cap stands at ₹6,581.98 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is SENORES PHARMACEUTICALS L stock performing today in the market?
SENORES PHARMACEUTICALS L stock opened at ₹1,442.80 and is currently trading at ₹1,428.40, showing a decline of ₹2.00 (0.14%). The intraday high is ₹1,465.90 and low is ₹1,420.00. The trading volume stands at 1,24,425 shares, indicating moderate market participation today.
08What is the P/E ratio of SENORES PHARMACEUTICALS L and what does it indicate?
SENORES PHARMACEUTICALS L has a Price-to-Earnings (P/E) ratio of 50.84, which means investors are willing to pay 50.84 for every ₹1 of earnings. With an EPS of ₹6.67, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about SENORES PHARMACEUTICALS L (SENORES) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.